therapies Archives - AudioMedica.com

Tagged: therapies

- in Cardiovascular
- — 6 Apr, 2008
Routine Angioplasty Recommended After Thrombolysis

Warren Cantor

Tony Gershlick
REFERENCE: Abstract 2404-3 SCAI-ACCi2 Late-Breaking Clinical Trials II: Acute Myocardial Infarction
Warren Cantor, University of Toronto
COMMENT: Tony Gershlick, Leicester University
A new study has shown important gains from adding angioplasty routinely to therapy for all
…
Read more
- in Oncology
- — 17 Mar, 2008
Front Line Therapy in Non-Small Cell Lung Cancer

Nick Thatcher
NICK THATCHER, Christie Hospital, Manchester
There is a proven benefit in survival if you give your patients cis-platinum based chemotherapy after resection for non-small cell lung cancer. Nick Thatcher emphasized this fact at the beginning of his
…
Read more
- in General Medicine
- — 17 Mar, 2008
New Targets Bring Promise For Lung Cancer Therapy

Egbert Smit
EGBERT SMIT, Free University of Amsterdam
There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He talked with Peter Goodwin about insulin-like
…
Read more
- in Oncology
- — 26 Feb, 2008
“Total Therapy” Possible Cure For Multiple Myeloma?

Bart Barlogie
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
BART BARLOGIE, University of Arkansas, Little Rock
A treatment known as “total therapy” could cure many patients with multiple myeloma, conference-goers have just heard. The targeted
…
Read more
- in News · Oncology
- — 26 Feb, 2008
Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma

Martin Dreyling
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He
…
Read more
- in News · Oncology
- — 26 Feb, 2008
Chronic Lymphocytic Leukemia After Fludarabine Failure

John Gribben
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
JOHN GRIBBEN, Bartholemews Hospital, London
New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as
…
Read more
- in Oncology
- — 25 Feb, 2008
Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon

Kenneth Anderson
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
KENNETH ANDERSON, Dana-Farber Cancer Institute, Boston
Multiple myeloma may soon be considered a chronic disease with cure on the horizon, thanks to an array of novel
…
Read more
$Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone$
- in Oncology
- — 1 Feb, 2008
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

Cora Sternberg
REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving
…
Read more
- in Oncology
- — 27 Jan, 2008
Gastrointestinal Cancers: Progress with Targeted Therapies

Robert Mayer
ROBERT MAYER, Dana-Farber Cancer Institute, Boston
One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some of the emerging new therapies being announced, for colorectal, liver and
…
Read more
- in Oncology
- — 15 Dec, 2007
New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer

Jose Baselga
JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and
…
Read more
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

Richard Stone
RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
…
Read more
- in Public Health
- — 9 Dec, 2007
No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia

Zakari Aliyu
REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
ZAKARI ALIYU, Howard University, Washington DC
Nigeria has the highest incidence of sickle cell anemia in the world, with over 150,000 children being born each year with
…
Read more

Tagged: therapies

Sign up for AudioMedica.com news